報價延遲最少15分鐘:2026/02/28 15:31 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.94 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.79/-0.74
|
|
企業價值
132.84M
|
| 資產負債 |
|
每股賬面淨值
0.72
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
683.00K
|
|
每股收益
0.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targetingtumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States. |
